Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Short Interest Update

Titan Pharmaceuticals, Inc. (NASDAQ:TTNPGet Free Report) was the target of a significant drop in short interest in the month of May. As of May 15th, there was short interest totalling 9,500 shares, a drop of 19.5% from the April 30th total of 11,800 shares. Approximately 1.5% of the shares of the company are sold short. Based on an average trading volume of 6,600 shares, the short-interest ratio is currently 1.4 days.

Titan Pharmaceuticals Stock Performance

Shares of TTNP opened at $6.51 on Friday. The business has a 50-day simple moving average of $6.86 and a two-hundred day simple moving average of $6.83. Titan Pharmaceuticals has a 52 week low of $5.00 and a 52 week high of $16.59.

Titan Pharmaceuticals (NASDAQ:TTNPGet Free Report) last released its earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($1.24) earnings per share (EPS) for the quarter. Titan Pharmaceuticals had a negative return on equity of 99.96% and a negative net margin of 2,014.71%.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on Titan Pharmaceuticals in a research note on Sunday. They issued a “sell” rating for the company.

Read Our Latest Research Report on Titan Pharmaceuticals

Titan Pharmaceuticals Company Profile

(Get Free Report)

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.

See Also

Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.